Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Show more
Location: 27 West 24th Street, New York, NY, 10010, United States | Website: https://www.tourmalinebio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
645.1M
52 Wk Range
$11.56 - $29.79
Previous Close
$25.11
Open
$25.11
Volume
293,636
Day Range
$24.72 - $25.53
Enterprise Value
405.8M
Cash
239.2M
Avg Qtr Burn
-21.57M
Insider Ownership
21.93%
Institutional Own.
89.97%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pacibekitug (TOUR006) Details Thyroid Eye Disease | Phase 2b Data readout | |
Pacibekitug (TOUR006) Details Atherosclerotic cardiovascular disease (ASCVD) | Phase 2 Update | |
FCR001 Details Scleroderma | Failed Discontinued |